NGNE Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-1.102

+11.31%

-1.225

+13.43%

-1.265

+20.48%

Estimates Revision

The market is revising No Change the revenue expectations for Neurogene Inc. (NGNE) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 21.89%.

EPS Estimates for FY2025

Revise Downward

-11.1%

In Past 3 Month

Stock Price

Go Up

+21.89%

In Past 3 Month

5 Analyst Rating

Wall Street analysts forecast NGNE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NGNE is 58.00 USD with a low forecast of 46.00 USD and a high forecast of 70.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

Current: 21.270

Low

46.00

Averages

58.00

High

70.00

Current: 21.270

Low

46.00

Averages

58.00

High

70.00

H.C. Wainwright

Buy

maintain

$65 -> $70

2025-11-13

Reason

H.C. Wainwright

Price Target

$65 -> $70

2025-11-13

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Neurogene (NGNE) to $70 from $65 and keeps a Buy rating on the shares. The firm believes the new NGN-401 data "highlights an absurdly inverted valuation dynamic" between Taysha Gene Therapies (TSHA) and Neurogene. Taysha still trades at multiples of Neurogene's valuation "despite the fact that NGN-401 has more advanced, durable, and clinically meaningful data," the analyst tells investors in a research note. The firm says Taysha's TSHA-102 still has no longitudinal patient-level detail and no evidence of accumulating multi-skill gains.

H.C. Wainwright

Buy

upgrade

$45 -> $65

2025-10-31

Reason

H.C. Wainwright

Price Target

$45 -> $65

2025-10-31

upgrade

Buy

Reason

H.C. Wainwright raised the firm's price target on Neurogene to $65 from $45 and keeps a Buy rating on the shares. The firm says a pediatric neurologist it spoke to sees "clean" safety, same vector/dose, and clearer regulatory footing for NGN-401. H.C. Wainwright upped its probability of sucess to 45% from 35%.

Craig-Hallum

initiated

$50

2025-06-18

Reason

Craig-Hallum

Price Target

$50

2025-06-18

initiated

Reason

Craig-Hallum initiated coverage of Neurogene with a Buy rating and $50 price target.

BMO Capital

Outperform

maintain

$22 -> $26

2025-06-12

Reason

BMO Capital

Price Target

$22 -> $26

2025-06-12

maintain

Outperform

Reason

BMO Capital raised the firm's price target on Neurogene to $26 from $22 and keeps an Outperform rating on the shares. BMO notes that the initial analysis of the most recently dosed 5 patients with NGN-401 was able to demonstrate ferritin control with no patients surpassing the 500 ng/mL level of clinical concern for HLH, hemophagocytic lymphohistiocytosis, and the firm states that it has more confidence in the company's ability to control reactions going forward, the analyst tells investors in a research note.

BMO Capital

Outperform

maintain

$16 -> $22

2025-05-20

Reason

BMO Capital

Price Target

$16 -> $22

2025-05-20

maintain

Outperform

Reason

BMO Capital raised the firm's price target on Neurogene to $22 from $16 and keeps an Outperform rating on the shares. The firm notes that the company's ASGCT presentations and the recent FDA earnings commentary gives it increased confidence in acceptance of non-placebo controlled trials, the analyst tells investors in a research note. Additional ASGCT presentations outline risk mitigation strategies which makes BMO more confident going forward, the firm added.

Baird

Outperform -> Neutral

downgrade

$38 -> $24

2025-05-16

Reason

Baird

Price Target

$38 -> $24

2025-05-16

downgrade

Outperform -> Neutral

Reason

Valuation Metrics

The current forward P/E ratio for Neurogene Inc (NGNE.O) is -4.20, compared to its 5-year average forward P/E of -6.08. For a more detailed relative valuation and DCF analysis to assess Neurogene Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.08

Current PE

-4.20

Overvalued PE

-3.46

Undervalued PE

-8.70

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

117.21

Current PS

0.00

Overvalued PS

436.27

Undervalued PS

-201.85

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

NGNE News & Events

Events Timeline

No data

News

9.5

11-13Newsfilter

Neurogene Announces Financial Results for Q3 2025 and Shares Recent Developments

6.0

11-13Benzinga

HC Wainwright & Co. Reaffirms Buy Rating on Neurogene, Increases Price Target to $70

9.0

11-06Newsfilter

Neurogene Doses First Participant in Embolden™ Trial for NGN-401 Gene Therapy Targeting Rett Syndrome

People Also Watch

Frequently Asked Questions

What is Neurogene Inc (NGNE) stock price today?

The current price of NGNE is 21.27 USD — it has increased 1.67 % in the last trading day.

What is Neurogene Inc (NGNE)'s business?

Neurogene Inc. is a clinical-stage biotechnology company. The Company, through its proprietary transgene regulation technology, Expression Attenuation via Construct Tuning (EXACT), is building a product portfolio of genetic medicines for rare neurological diseases with high unmet needs not otherwise addressable by conventional gene therapy. Its clinical-stage program, NGN-401, utilize the EXACT platform, which is in development for the treatment of Rett syndrome, a disease with a patient population that has a significant unmet need, and that ultimately progresses to substantial neurological and physical impairment and premature death. NGN-401 is being evaluated in female patients with Rett syndrome in a Phase 1/2 open-label, multi-center clinical trial that assesses the safety, tolerability, and efficacy of two doses of NGN-401 delivered using a one-time intracerebral ventricular (ICV) procedure. It is also developing NGN-101 for the treatment of CLN5 Batten disease.

What is the price predicton of NGNE Stock?

What is Neurogene Inc (NGNE)'s revenue for the last quarter?

Neurogene Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is Neurogene Inc (NGNE)'s earnings per share (EPS) for the last quarter?

Neurogene Inc. EPS for the last quarter amounts to -0.99 USD, decreased -16.81 % YoY.

What changes have occurred in the market's expectations for Neurogene Inc (NGNE)'s fundamentals?

How many employees does Neurogene Inc (NGNE). have?

Neurogene Inc (NGNE) has 107 emplpoyees as of December 15 2025.

What is Neurogene Inc (NGNE) market cap?

Today NGNE has the market capitalization of 324.05M USD.